What is it about?
This study provides the rationale for the design of a new clinical protocol to assess the anticancer activity of the trastuzumab emtansine (T-DM1, an anti-HER2 antibody-drug linked to the anti-mitotic agent emtansine) and DHA (the active metabolite of artemisinin, the active principle of Artemisia annua) combination in patients with HER2-positive breast cancer.
Featured Image
Photo by Angiola Harry on Unsplash
Read the Original
This page is a summary of: DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines, Cells, May 2020, MDPI AG,
DOI: 10.3390/cells9051260.
You can read the full text:
Contributors
The following have contributed to this page
